Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Fig. 1

FAK inhibition reprograms the immuno-suppressive environment in pancreatic tumors rendering them sensitive to immune checkpoint blockade. (1) Pancreatic Ductal Adenocarcinoma contains a highly fibrotic and immuno-suppressive microenvironment. (2) Inhibition of FAK kinase activity results in extensive remodeling of the fibrotic and immuno-suppressive tumor niche that results in a modest improvement in survival time. (3) Combining the effects of FAK inhibition with checkpoint blockade and gemcitabine chemotherapy results in a significant improvement in survival time and even long-term survival

Back to article page